National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 43 of 66
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia
NCT00217646
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
NCT00288067
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
NCT00112905
Genetic Predictors of Cardiovascular Disease
NCT00339599
Intensity Modulated Radiation Therapy for Prostate Cancer
NCT00214422
Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia
NCT00303823
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00262847
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
NCT00245102
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma
NCT00132028
Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer
NCT00179309
Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors
NCT00255658
Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer
NCT00103194
Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer
NCT00100750
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
NCT00121225
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
NCT00244881
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
NCT00253630
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
NCT00238303
Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
NCT00281944
Radiation Therapy in Treating Patients With Cervical Cancer
NCT00278304
Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer
NCT00096109
Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
NCT00091078
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
NCT00126581
Effect of High-Legume Diet on Colorectal Cancer Risk
NCT00339469
PRelationship Between Physical Activity and Cancer Ris
NCT00521651
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
NCT00217412
Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome
NCT00342602
Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
NCT00243035
Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)
NCT00111384
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
NCT00238420
Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer
NCT00124917
Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
NCT00117845
3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
NCT00081276
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
NCT00138177
Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors
NCT00287937
Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery
NCT00217542
Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
NCT00217503
Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00118183
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT00103259
Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer
NCT00182689
Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer
NCT00182702
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00227513
Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
NCT00126607
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a
NCT00117013
Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer
NCT00118040
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
NCT00114738
Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers
NCT00342641
Vaccine and Antibody Treatment of Prostate Cancer
NCT00113984
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
NCT00121251
Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
NCT00119249
Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT00084682
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.